A biotech spinout developing patented microneedle technology as a versatile drug delivery platform.

•Our first product targets nail fungal infections, a $6B global market.

•Our pipeline includes applications for skin cancer, skin aging, peptides and migraines.

•We have completed proof of concept, all preclinical data is ready, and our clinical roadmap is in place.

•Clinical trials are set to begin in Q1-2026.\ •Experienced management team with strong industrial track record.